Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s share price gapped down before the market opened on Friday . The stock had previously closed at $10.27, but opened at $9.66. Telix Pharmaceuticals shares last traded at $9.4810, with a volume of 60,777 shares traded.

Analysts Set New Price Targets

TLX has been the subject of several research reports. Wall Street Zen upgraded Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Citigroup lifted their price objective on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Monday, April 20th. Finally, Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $21.13.

Telix Pharmaceuticals Price Performance

The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The company’s 50 day simple moving average is $9.86 and its 200 day simple moving average is $8.75.

Telix Pharmaceuticals (NASDAQ:TLX) last released its earnings results on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). The business had revenue of $206.72 million for the quarter, compared to analysts’ expectations of $421.50 million. As a group, sell-side analysts expect that Telix Pharmaceuticals Limited will post 0.09 EPS for the current year.

Insider Buying and Selling

In other news, CEO Christian Behrenbruch bought 33,435 shares of the stock in a transaction on Wednesday, April 29th. The stock was purchased at an average cost of $14.87 per share, with a total value of $497,178.45. Following the purchase, the chief executive officer owned 20,742,935 shares of the company’s stock, valued at approximately $308,447,443.45. The trade was a 0.16% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link.

Institutional Trading of Telix Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Portland Investment Counsel Inc. purchased a new stake in Telix Pharmaceuticals in the 3rd quarter worth approximately $1,225,000. Mariner LLC purchased a new stake in Telix Pharmaceuticals in the 4th quarter worth approximately $274,000. JPMorgan Chase & Co. purchased a new stake in Telix Pharmaceuticals in the 3rd quarter worth approximately $243,000. IHT Wealth Management LLC acquired a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at $213,000. Finally, Vident Advisory LLC acquired a new position in shares of Telix Pharmaceuticals in the 4th quarter valued at $204,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.